Interview with Dirceu Barbano, Director, ANVISA
10 days ago, your Swedish counterpart Mats Larsson made a technical visit here at ANVISA and said he had a lot to learn. What is it about ANVISA that can…
Address: Praça São Marcos, 624 05455-050 – São Paulo – SP,Brazil
Tel: 0800-772-4656
Web: http://www.ferring.com.br/
In 1950 in Malmö, Sweden, Dr. Frederik Paulsen founded Laboratoriet Nordiska hormone, which in 1954 changed its name to Ferring.
A world leader in peptide hormones, Ferring was a pioneer in developing and selling pharmaceutical products based on natural hormones, the pituitary-produced peptide. Dr. Paulsen was convinced that these new compounds could be used to supplement deficiencies and abnormalities, making an invaluable role in the treatment of various diseases.
Five decades later, Dr. Paulsen’s predictions have proven inaccurate. Today, the peptides are widely used in various treatments of Ferring.
Over the past years Ferring has expanded its activities beyond its European base and now have subsidiaries operating in over 40 countries, including Brazil, which is the company’s fastest-growing subsidiary. Its annual turnover is 700 million and has over 3,000 employees. Over the next three to five years, the group aims to triple sales in Brazil.
Propess, BioGaia, DDAVP, Choragon, Bravelle, FemLab, Menogon
10 days ago, your Swedish counterpart Mats Larsson made a technical visit here at ANVISA and said he had a lot to learn. What is it about ANVISA that can…
Yesterday, Minister Pimentel unveiled the Brazil Maior plan to increase competitiveness and growth across a variety of industrial sectors. If you had to give recommendations to improve the Brazilian pharmaceutical…
In the past four years, Brazil’s pharmaceutical market has more than doubled. To what do you attribute this astounding growth? In Brazil there is a strong income inequality. As the…
Sao Paulo state is responsible for some 85% of pharmaceutical production, and last week Minister Pimentel was in the city of Sao Paulo elaborating on his BrazilMaior plan with strategic…
Besins finally arrived in Brazil in 2010. In addition to introducing the company to the market, would you also elaborate on the strategic motivation behind this decision? Besins Healthcare is…
Much has changed at Bomi since we last met in 2007. At that time, you were launching your new facilities, with 72,000 square metres of built area, 14 metres free…
Two days ago, the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan…
Your position unites two somewhat incongruous titles – Director of Sustainability, and New Business. How did this come to be, and what if any overlap is there between these two…
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
What have been some of the recent milestones and achievements contributing to AstraZeneca Brazil’s status as the country’s fastest growing MNC? What happened in the last 10 years was a…
Mr. Mauricio, you’ve mentioned that Brazil is a different kind of market for Octapharma, one strongly based on price, and that because of this it’s hard to add value. Could…
When we met Servier Brazil five years ago the company had major ambitions: ‘grow more than 10% for the five following years’. How have these expectations turned out to be?…
See our Cookie Privacy Policy Here